Kyowa Kirin Co Ltd
TSE:4151

Watchlist Manager
Kyowa Kirin Co Ltd Logo
Kyowa Kirin Co Ltd
TSE:4151
Watchlist
Price: 2 494 JPY -0.8%
Market Cap: 1.3T JPY

Kyowa Kirin Co Ltd
Accounts Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Kyowa Kirin Co Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Kyowa Kirin Co Ltd
TSE:4151
Accounts Receivables
ÂĄ151.8B
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
4%
Takeda Pharmaceutical Co Ltd
TSE:4502
Accounts Receivables
ÂĄ689B
CAGR 3-Years
-3%
CAGR 5-Years
-2%
CAGR 10-Years
4%
Daiichi Sankyo Co Ltd
TSE:4568
Accounts Receivables
ÂĄ616.9B
CAGR 3-Years
23%
CAGR 5-Years
20%
CAGR 10-Years
9%
Otsuka Holdings Co Ltd
TSE:4578
Accounts Receivables
ÂĄ525.6B
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
5%
Chugai Pharmaceutical Co Ltd
TSE:4519
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Accounts Receivables
ÂĄ702.9B
CAGR 3-Years
16%
CAGR 5-Years
16%
CAGR 10-Years
7%
No Stocks Found

Kyowa Kirin Co Ltd
Glance View

Market Cap
1.3T JPY
Industry
Pharmaceuticals

Kyowa Kirin Co., Ltd. stands as a notable presence in the global pharmaceutical landscape, having evolved from its roots in Japan into a significant force in medical innovation. This company, originally established from the merger of Kyowa Hakko Kogyo and Kirin Pharma, focuses on the development and commercialization of biopharmaceuticals that tackle complex medical conditions, primarily within the fields of oncology, nephrology, immunology, and neurology. With a strategy deeply rooted in research and development, Kyowa Kirin harnesses its proprietary antibody technologies and innovative approaches to deliver therapeutic solutions, fostering partnerships that expand its impact and reach. Their commitment to scientific progress is supplemented by a robust pipeline of investigational drugs, demonstrating their dedication to addressing unmet medical needs. Kyowa Kirin operates primarily on a business model that derives revenues from the successful commercialization of its pharmaceutical products. The company navigates the delicate balance between high-stakes investment in R&D and the potential high rewards that come from developing effective new treatments. By consistently bringing innovative therapies to market, they generate revenue through direct sales, collaborations, and licensing agreements within both domestic and international spheres. Additionally, their strategic alliances with biotech firms and research institutions globally enable them to enhance their R&D capabilities, ensuring a steady flow of new drugs that sustain their growth and solidify their competitive edge in the highly regulated and competitive pharmaceutical sector.

Intrinsic Value
2 033.97 JPY
Overvaluation 18%
Intrinsic Value
Price

See Also

What is Kyowa Kirin Co Ltd's Accounts Receivables?
Accounts Receivables
151.8B JPY

Based on the financial report for Sep 30, 2025, Kyowa Kirin Co Ltd's Accounts Receivables amounts to 151.8B JPY.

What is Kyowa Kirin Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
4%

Over the last year, the Accounts Receivables growth was 8%. The average annual Accounts Receivables growth rates for Kyowa Kirin Co Ltd have been 14% over the past three years , 13% over the past five years , and 4% over the past ten years .

Back to Top